GURUFOCUS.COM » STOCK LIST » USA » NAS » Amgen Inc (NAS:AMGN) » Definitions » Ending Cash Position
Switch to:

Amgen (NAS:AMGN) Ending Cash Position

: $34,741 Mil (As of Sep. 2023)
View and export this data going back to 1983. Start your Free Trial

Amgen's Ending Cash Position for the quarter that ended in Sep. 2023 was $34,741 Mil.

Amgen's quarterly Ending Cash Position increased from Mar. 2023 ($31,560 Mil) to Jun. 2023 ($34,248 Mil) and increased from Jun. 2023 ($34,248 Mil) to Sep. 2023 ($34,741 Mil).

Amgen's annual Ending Cash Position increased from Dec. 2020 ($6,266 Mil) to Dec. 2021 ($7,989 Mil) but then declined from Dec. 2021 ($7,989 Mil) to Dec. 2022 ($7,629 Mil).

Amgen Ending Cash Position Historical Data

The historical data trend for Amgen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Ending Cash Position
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,945.00 6,037.00 6,266.00 7,989.00 7,629.00

Amgen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Ending Cash Position Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,502.00 7,629.00 31,560.00 34,248.00 34,741.00

Amgen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Amgen's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7989+-360
=7,629

Amgen's Ending Cash Position for the quarter that ended in Sep. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=34248+493
=34,741

Amgen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Amgen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (NAS:AMGN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (NAS:AMGN) » Definitions » Ending Cash Position
Comparable Companies
NYSE:PFE NYSE:BMY NAS:GILD NYSE:ABBV NAS:BIIB NYSE:MRK NYSE:OGN NAS:AMRN NAS:SCLX NAS:MIRA NYSE:LLY NYSE:JNJ XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276
Traded in Other Exchanges
AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Website
https://www.amgen.com
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Executives
Matthew C. Busch officer: VP, Finance & CAO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Michael V Drake director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Derek Miller officer: SVP, Human Resources ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Rachna Khosla officer: SVP, Business Development ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Amy E Miles director
Linda H. Louie officer: VP, Finance & CAO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Nancy A. Grygiel officer: SVP & CCO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Peter H. Griffith officer: EVP & CFO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Murdo Gordon officer: EVP Global Commercial Ops C/O BRISTOL-MYERS SQUIBB COMPANY, 345 PARK AVE, NEW YORK NY 10154
David M Reese officer: EVP, Research and Development ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Wanda M Austin director 6001 BOLLINGER CANYON ROAD, SAN RAMON CA 94583
Charles M Holley director
Lori A Johnston officer: SVP, HR C/O AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320